Want to see FBLG full AI Analyst Report?
Top Page
FibroBiologics, Inc.
(NASDAQ:FBLG)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.50
▲(111.27% Upside)
Action:Reiterated
Date:08/24/26
The score is weighed down primarily by weak financial performance (no revenue, large ongoing losses, and persistent cash burn), despite balance sheet deleveraging. Technicals show short-term strength but overbought conditions and a weak long-term trend. Corporate events add meaningful listing-risk uncertainty, while valuation remains constrained by negative earnings and no dividend support.
Positive Factors
Improved balance sheet and lower leverage
Substantial debt reduction and positive equity provide a stronger capitalization base than in 2024. This lowers financial leverage and may improve flexibility as the company funds research, although ongoing losses continue to consume assets.
Negative Factors
No revenue and persistent losses
A lack of revenue means the company has no commercial cash-generating engine to offset research and operating costs. Persistently large losses, after rising from about $5.1M in 2022, indicate substantial dependence on future financing or successful product development.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved balance sheet and lower leverage
Substantial debt reduction and positive equity provide a stronger capitalization base than in 2024. This lowers financial leverage and may improve flexibility as the company funds research, although ongoing losses continue to consume assets.
Read all positive factors
FibroBiologics, Inc. (FBLG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.99M
Dividend YieldN/A
Average Volume (3M)978.93K
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue GrowthN/A
EPS Growth22.10%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.57
Shares Outstanding6,658,193
10 Day Avg. Volume1,423,641
30 Day Avg. Volume978,931
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside745.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.01
Revenue Forecast (FY)N/A
FibroBiologics, Inc. Business Overview & Revenue Model
Company Description
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to addre...
How the Company Makes Money
null...
FibroBiologics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -234.00K | -832.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -17.14M | -17.61M | -10.57M | -15.90M | -4.37M | -1.58M |
| Net Income | -18.14M | -18.65M | -11.16M | -16.48M | -5.12M | -1.58M |
Balance Sheet | ||||||
| Total Assets | 7.93M | 9.62M | 16.45M | 11.82M | 4.82M | 468.00K |
| Cash, Cash Equivalents and Short-Term Investments | 3.52M | 4.89M | 13.98M | 9.16M | 2.27M | 407.00K |
| Total Debt | 1.46M | 2.41M | 10.55M | 1.75M | 7.52M | 1.30M |
| Total Liabilities | 3.29M | 3.46M | 13.71M | 10.57M | 8.82M | 1.76M |
| Stockholders Equity | 4.64M | 6.16M | 2.73M | 1.25M | -4.00M | -1.29M |
Cash Flow | ||||||
| Free Cash Flow | -14.80M | -16.66M | -12.09M | -6.90M | -4.07M | -1.41M |
| Operating Cash Flow | -14.79M | -16.39M | -11.90M | -6.40M | -4.07M | -1.41M |
| Investing Cash Flow | -6.00K | -262.00K | -184.00K | -495.00K | 0.00 | 0.00 |
| Financing Cash Flow | 9.47M | 7.57M | 16.91M | 13.79M | 5.92M | 1.82M |
FibroBiologics, Inc. Technical Analysis
Neutral
0.71
Price Trends
0.90
Positive
1.07
Positive
3.47
Negative
Market Momentum
0.14
Negative
70.69
Negative
80.70
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBLG, the sentiment is Neutral. The current price of 0.71 is below the 20-day moving average (MA) of 1.04, below the 50-day MA of 0.90, and below the 200-day MA of 3.47, indicating a neutral trend. The MACD of 0.14 indicates Negative momentum. The RSI at 70.69 is Negative, neither overbought nor oversold. The STOCH value of 80.70 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FBLG.
FibroBiologics, Inc. Risk Analysis
FibroBiologics, Inc. disclosed 66 risk factors in its most recent earnings report. FibroBiologics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
FibroBiologics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $14.45M | -21.97 | -5.42% | ― | ― | 46.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $13.20M | -1.40 | -47.86% | ― | -93.71% | 23.89% | |
48 Neutral | $6.06M | -0.39 | -281.30% | ― | ― | 90.37% | |
45 Neutral | $8.99M | -0.24 | -767.07% | ― | ― | 22.10% | |
45 Neutral | $3.30M | -0.11 | 805.67% | ― | -62.17% | 85.37% |
* Healthcare Sector Average
FBLG
FibroBiologics, Inc.
1.40
-10.70
-88.43%
BLRX
Bioline RX Ltd Sponsored ADR
2.85
-0.76
-21.05%
CRIS
Curis
1.59
-31.81
-95.24%
SYBX
Synlogic
1.21
-0.25
-17.12%
LEXX
Lexaria Bioscience
11.60
-2.34
-16.76%
PCSA
Processa Pharmaceuticals
2.18
-3.41
-61.00%
FibroBiologics, Inc. Corporate Events
Business Operations and StrategyExecutive/Board Changes
FibroBiologics Adds Leigh Steinberg to Board for Growth
Positive
Aug 24, 2026
On August 20, 2026, FibroBiologics appointed Leigh Steinberg as a Class II director to its board, with his term running until the 2028 annual meeting of stockholders, under standard non-employee director compensation and indemnification arrangemen...
Delistings and Listing ChangesRegulatory Filings and Compliance
FibroBiologics Faces Nasdaq Delisting, Appeals Planned
Negative
Jul 24, 2026
On July 22, 2026, FibroBiologics, Inc. received a Staff Determination letter from Nasdaq stating that its securities are subject to delisting from The Nasdaq Capital Market because the company’s bid price closed below $1.00 per share for 30 ...
Executive/Board Changes
FibroBiologics Appoints NASA Scientist Kate Rubins to Board
Positive
Jul 9, 2026
On July 2, 2026, FibroBiologics director Matt Link resigned from the company’s board, and on July 8, 2026, the board appointed microbiologist and retired NASA astronaut Kathleen “Kate” Rubins, Ph.D., as a Class III director with ...
Business Operations and StrategyPrivate Placements and Financing
FibroBiologics Secures New Private Placement Financing
Positive
Jun 29, 2026
On June 25, 2026, FibroBiologics, Inc. entered into a securities purchase agreement for an at-the-market private placement with an accredited investor that generated $3 million in gross proceeds and approximately $2.6 million in net proceeds after...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingShareholder Meetings
FibroBiologics Shareholders Approve New 2026 Equity Plan
Positive
Jun 23, 2026
FibroBiologics, Inc. held its 2026 Annual Meeting of Stockholders on June 22, 2026, where shareholders approved a new 2026 Equity and Incentive Compensation Plan to replace the 2022 Stock Plan, authorizing 2,061,968 shares for awards and adding an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.